Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders
Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg. The post Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders appeared first on GEN - Genetic Engineering and Biotechnology News .
Eli Lilly showcased early positive clinical results for its GIP/GLP-1 receptor agonist candidate, brenipatide, at Psych Congress 2026, discussing its potential in treating substance use, psychiatric, and immunologic disorders. Brenipatide is a dual-agonist of GLP-1 and GIP receptors, similar to the blockbuster drugs Mounjaro and Zepbound.
Unlike its counterpart, brenipatide targets central nervous system and inflammatory pathways linked to reward and addiction in the brain. At the conference, Lilly presented data from its Phase I J2S-MC-GZMD trial, evaluating the safety, pharmacokinetics, and pharmacodynamics of brenipatide in healthy, overweight, and obese participants.
The drug demonstrated a mean half-life of 9.08 to 12.5 days, with higher doses leading to longer half-lives. Researchers concluded that the extended half-life supports weekly maintenance doses for substance use, psychiatric, and immunologic disorders. Lilly is developing two Phase III trials to assess brenipatide in major depressive disorder and alcohol use disorder, aiming to enroll around 1,000 participants across 14 countries.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
